Published on 22/12/2025
How to Integrate Patient-Reported Outcomes (PROs) in Phase 2 Clinical Trial Design
Introduction
As the focus of clinical research shifts toward patient-centered drug development, the integration of Patient-Reported Outcomes (PROs) in Phase 2 trials is gaining traction. PROs provide direct insight into how patients feel, function, and experience side effects during treatment. These subjective endpoints are valuable not only for regulatory and payer discussions but also for optimizing dose and measuring early efficacy. This tutorial discusses why and how to incorporate PROs into the design of Phase 2 trials to ensure meaningful and measurable patient impact.
What Are Patient-Reported Outcomes (PROs)?
A Patient-Reported Outcome is any report of a patient’s health condition that comes directly from the patient, without interpretation by clinicians or others. PROs commonly assess:
- Symptoms: Pain, fatigue, nausea
- Function: Physical, emotional, cognitive ability
- Quality of Life (QoL): Overall well-being and daily living impact
- Treatment satisfaction: Convenience, expectations, burden
Why Use PROs in Phase 2 Trials?
- Patient perspective: Captures subjective benefits or burdens not visible in clinical data
- Early signal of impact: Detects improvements in symptoms before hard endpoints like survival
- Dose selection: Identifies tolerable and effective dose based on patient feedback
- Regulatory and HTA readiness: PROs support label claims
When to Include PROs in Phase 2?
- When the investigational product targets symptom relief or chronic conditions
- When a balance of efficacy and tolerability needs to be explored
- When preparing for Phase 3 label-enabling endpoints
- When patient voice is critical for trial success (e.g., rare disease, oncology)
Types of PRO Instruments
1. Generic Instruments
- SF-36: Measures 8 health domains (QoL)
- EQ-5D: Assesses mobility, self-care, pain/discomfort, anxiety/depression
2. Disease-Specific Instruments
- FACT-G: Functional Assessment of Cancer Therapy (oncology)
- HAQ-DI: Health Assessment Questionnaire (rheumatoid arthritis)
- ACQ: Asthma Control Questionnaire
3. Symptom Scales
- VAS (Visual Analog Scale): Pain, nausea, fatigue
- BPI: Brief Pain Inventory
4. Custom Tools
Developed with patient input for trials where validated tools don’t exist; often used in rare diseases.
Design and Implementation Strategies
1. Define the PRO Objective
- Symptom improvement?
- Function restoration?
- Treatment satisfaction?
2. Choose Validated Tools
- Ensure the instrument is validated in the target population
- Translate and culturally adapt if conducting multinational trials
3. Specify Timepoints
- Baseline and periodic follow-ups (e.g., Week 4, 8, 12)
- End-of-treatment and follow-up visits
4. Mode of Collection
- ePRO via handheld devices or web portals
- Paper-based forms only if electronic systems are unavailable
Data Management and Analysis
- Use standardized scoring algorithms
- Define thresholds for meaningful change (MCID – Minimally Clinically Important Difference)
- Apply mixed models or repeated measures for longitudinal analysis
- Ensure missing data strategies are pre-specified
Regulatory Perspective on PROs
FDA
- Supports PROs that are conceptually sound and well-documented
- Issued the PRO Guidance for Industry (2009)
- Label claims based on PROs require rigorous validation
EMA
- Encourages PRO inclusion in early-phase and confirmatory studies
- Recommends EQ-5D for health economics assessments
CDSCO
- Accepts PROs in Indian clinical trials when properly translated and validated
Case Example: PRO Use in a Chronic Pain Phase 2 Study
A randomized Phase 2 trial compared two doses of a new analgesic. Patients completed daily pain VAS and weekly BPI assessments. Both arms showed similar pain reduction, but the lower dose was favored for tolerability and overall treatment satisfaction—helping guide Phase 3 design.
Best Practices
- Engage patients during trial design and instrument selection
- Use ePRO systems to reduce data entry errors and improve compliance
- Predefine PRO endpoints and statistical handling in protocol/SAP
- Train site staff on the importance of accurate and timely PRO collection
Conclusion
Integrating PROs into Phase 2 clinical trials offers a valuable window into patient experience, complements traditional endpoints, and enhances development strategy. As regulatory bodies and payers increasingly value real-world relevance, PROs serve as a bridge between clinical efficacy and actual benefit. When designed and implemented effectively, PROs empower the patient voice and contribute to more meaningful therapeutic innovation.